Sola-Munoz S, Jorge M, Jimenez-Fabrega X, Jimenez-Delgado S, Azeli Y, Marsal JR, Jordan S, Mauri J, Jacob J. Prehospital stratification and prioritisation of non-ST-segment elevation acute coronary syndrome patients (NSTEACS): the MARIACHI scale. Intern Emerg Med. 2023 Aug 2;18(5):1317-27. doi: 10.1007/s11739-023-03274-z
Carrigan G, Bradbury BD, Brookhart MA, Capra WB, Chia V, Rothman KJ, Sarsour K, Taylor MD, Brown JS. External comparator groups derived from real-world data used in support of regulatory decision making: use cases and challenges. Curr Epidemiol Rep. 2022 Dec;9:326-37. doi: 10.1007/s40471-022-00305-9
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Margulis AV, Anthony M, Rivero-Ferrer E. Drug safety in pregnancy: review of study approaches requested by regulatory agencies. Curr Epidemiol Rep. 2019 Sep;6(3):380-9. doi: 10.1007/s40471-019-00212-6
Kamptner NL, Teyber FH, Rockwood NJ, Drzewiecki D. Evaluating the efficacy of an attachment-informed psychotherapeutic program for incarcerated parents. J Prison Educ Reentr. 2017 Dec;4(2):62-81.
Ruetsch C, Tkacz J, Nadipelli VR, Brady BL, Ronquest N, Un H, Volpicelli J. Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes. Am J Manag Care. 2017 Jun 1;23(6):e172-9.
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
White C, Taychakhoonavudh S, Parikh RC, Franzini L. Roles of prices, poverty, and health in medicare and private spending in Texas. Am J Manag Care. 2015 May 1;21(5):e303-11.
Andrews EB, Margulis AV, Tennis PS, West SL. Opportunities and challenges in using epidemiologic methods to monitor drug safety in the era of large automated health databases. Curr Epidemiol Rep. 2014 Oct 12;1(4):194-205.
Colla CH, Schpero WL, Gottlieb DJ, McClurg AB, Albert PG, Baum N, Finison K, Franzini L, Kitching G, Knudson S, Parikh RC, Symes R, Fisher ES. Tracking spending among commercially insured beneficiaries using a distributed data model. Am J Manag Care. 2014 Aug;20(8):650-7.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Saffar D, Williams K, Lafata JE, Divine G, Pladevall M. Racial disparities in lipid control in patients with diabetes. Am J Manag Care. 2012 Jun 1;18(6):303-11.
Farkouh RA, Wilson MR, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with first-line early parkinson disease therapies. Am J Manag Care. 2012 May 1;4(3):99-107.
Yen L, Davis KL, Hodgkins P, Loftus EVJr, Erder MH. Direct medical costs of diverticulitis in a US managed care population. Am J Manag Care. 2012;4(5):e118-29.
Greene BL, Brown TM, Miller JD, Harshman R, Richerson G, Doyle JJ. Economic impact of the BP downshift program on blood pressure control among commercial driver license employees. Poster presented at the 2008 Academy of Managed Care Pharmacy Educational Conference; October 2008. [abstract] Am J Manag Care. 2008 Oct; 14(7).
Hadker N, Greene B, Brown TM, Harshman R, Richerson G, Turner B. Impact of the BP downshift program on blood pressure control among commercial driver's license employees: a managed care perspective. Am J Manag Care. 2007 Mar;13(2).
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Zarkin GA, Bala MV, Calingaert B, VanderLugt JT. The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythm. Am J Manag Care. 1997 Jan 1;3(9):1387-94.